Patents by Inventor Alfredo Nicosia
Alfredo Nicosia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240091338Abstract: The present invention relates to administration regimens which are particularly suited for vaccine composition comprising polynucleotides which encode immunogenic polypeptides. Said administration regimens involve the repeated administration of a vaccine composition and enhance the immune response against the immunogenic polypeptide.Type: ApplicationFiled: February 28, 2023Publication date: March 21, 2024Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Alfredo Nicosia, Ricardo Cortese, Alessandra Vitelli
-
Publication number: 20240075125Abstract: The invention relates to an expression system comprising polynucleotides encoding proteins, wherein the expression system comprises a first polynucleotide encoding at least one protein, peptide or variant thereof, which induces a T cell response, and a second polynucleotide encoding at least one protein, peptide or variant thereof, which induces an anti-pathogenic B cell response. The invention further relates to protein mixtures encoded by the expression system and cells comprising the expression system or the protein mixture and pharmaceutical compositions comprising the expression system or the protein mixture.Type: ApplicationFiled: May 22, 2023Publication date: March 7, 2024Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Alessandra Vitelli, Alfredo Nicosia, Riccardo Cortese
-
Patent number: 11913013Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).Type: GrantFiled: July 30, 2021Date of Patent: February 27, 2024Assignee: SABIN VACCINE INSTITUTEInventors: Nancy J. Sullivan, Gary J. Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca
-
Patent number: 11912743Abstract: Polypeptides comprising a fragment of a teleost invariant chain fused to one or more antigens can enhance T cell response. Alternatively a teleost invariant chain fused to one or more antigens or antigenic fragments thereof can be used. A polynucleotide encoding such polypeptides, vectors comprising such polynucleotides, collection of vectors comprising such polynucleotides are also disclosed. The use of such polypeptides, polynucleotides, vectors for treating or preventing diseases, in particular tumor diseases are also encompassed by the present invention. The teleost invariant chain polypeptides or fragments thereof act as “T cell enhancer” converting non-immunogenic antigenic sequences into immunogenic T cell antigens.Type: GrantFiled: November 2, 2018Date of Patent: February 27, 2024Assignee: NOUSCOM AGInventors: Alfredo Nicosia, Elisa Scarselli, Armin Lahm, Antonella Folgori
-
Patent number: 11701422Abstract: The invention relates to an expression system comprising polynucleotides encoding proteins, wherein the expression system comprises a first polynucleotide encoding at least one protein, peptide or variant thereof, which induces a T cell response, and a second polynucleotide encoding at least one protein, peptide or variant thereof, which induces an anti-pathogenic B cell response. The invention further relates to protein mixtures encoded by the expression system and cells comprising the expression system or the protein mixture and pharmaceutical compositions comprising the expression system or the protein mixture.Type: GrantFiled: February 25, 2020Date of Patent: July 18, 2023Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Alessandra Vitelli, Alfredo Nicosia, Riccardo Cortese
-
Patent number: 11643666Abstract: The present invention relates to a cell line, use of the cell line and a method for producing infectious viral particles using said cell line.Type: GrantFiled: October 25, 2018Date of Patent: May 9, 2023Assignee: NOUSCOM AGInventors: Stefano Colloca, Alfredo Nicosia
-
Patent number: 11578109Abstract: This invention relates to a method of selecting a collection of frame-shift peptides (CFSPs) to produce a universal cancer vaccine peptide collection (CVP) for prophylaxis and treatment of patients with hereditary and sporadic micro-satellite instability (MSI) tumors. This invention relates as well to a method of producing a CVP by selecting a subset of frame-shift peptides (FSPs) from the CFSP and optionally modifying the FSP's amino acid (aa) sequence to generate modified FSPs (mFSPs). The invention further relates to nucleic acid collections encoding a CVP of FSPs and/or mFSPs in one or more vaccine vectors that can be used also simultaneously. These CVPs, nucleic acids and vectors are used for the prophylaxis or treatment of MSI cancers.Type: GrantFiled: July 12, 2018Date of Patent: February 14, 2023Assignee: NOUSCOM AGInventors: Alfredo Nicosia, Elisa Scarselli, Guido Leoni, Armin Lahm
-
Patent number: 11498956Abstract: The present application provides inter alia a fusion protein comprising a polypeptide wherein the polypeptide consists of a fragment of invariant chain which is operably linked to an antigenic sequence and wherein the fragment of invariant chain consists of a portion of residues 17-97 of SEQ ID NO: 1, wherein the portion comprises at least 5 contiguous residues from residues 77-92 of SEQ ID NO: 1.Type: GrantFiled: August 23, 2017Date of Patent: November 15, 2022Assignees: GLAXOSMITHKLINE BIOLOGICALS SA, UNIVERSITY OF COPENHAGENInventors: Maria Rosaria Bassi, Riccardo Cortese, Anna Morena D'Alise, Antonella Folgori, Peter Johannes Holst, Alfredo Nicosia
-
Publication number: 20220220157Abstract: There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and (c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.Type: ApplicationFiled: January 25, 2022Publication date: July 14, 2022Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Virginia AMMENDOLA, Stefano COLLOCA, Riccardo CORTESE, Fabiana GRAZIOLI, Alfredo NICOSIA, Alessandra VITELLI
-
Publication number: 20220204566Abstract: There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and (c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.Type: ApplicationFiled: December 30, 2021Publication date: June 30, 2022Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Stefano COLLOCA, Virginia AMMENDOLA, Fabiana GRAZIOLI, Alessandra Franz VITELLI, Alfredo NICOSIA, Riccardo CORTESE
-
Patent number: 11278614Abstract: The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.Type: GrantFiled: February 5, 2020Date of Patent: March 22, 2022Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Stefano Colloca, Riccardo Cortese, Antonella Folgori, Alfredo Nicosia
-
Publication number: 20220064669Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).Type: ApplicationFiled: July 30, 2021Publication date: March 3, 2022Inventors: Nancy J. Sullivan, Gary J. Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca
-
Patent number: 11254710Abstract: There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and (c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.Type: GrantFiled: June 10, 2016Date of Patent: February 22, 2022Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Stefano Colloca, Virginia Ammendola, Fabiana Grazioli, Alessandra Franz Vitelli, Alfredo Nicosia, Riccardo Cortese
-
Patent number: 11254711Abstract: There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and (c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.Type: GrantFiled: June 10, 2016Date of Patent: February 22, 2022Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Virginia Ammendola, Stefano Colloca, Riccardo Cortese, Fabiana Grazioli, Alfredo Nicosia, Alessandra Vitelli
-
Patent number: 11214599Abstract: The present invention relates to novel adenovirus strains with an improved seroprevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleotides encoding the same. Also provided is a vector comprising the isolated polynucleotide according to the invention and adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention and a pharmaceutical composition comprising said vector, adenovirus, polypeptide and/or polynucleotide. The invention also relates to the use of the isolated polynucleotides, the isolated polypeptides, the vector, the adenoviruses and/or the pharmaceutical composition for the therapy or prophylaxis of a disease.Type: GrantFiled: December 11, 2019Date of Patent: January 4, 2022Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Stefano Colloca, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Maria Ambrosio
-
Publication number: 20210379169Abstract: The present invention relates to polypeptides comprising a fragment of a teleost invariant chain optionally fused to one or more antigens or a teleost invariant chain fused to one or more antigens or antigenic fragments thereof, a polynucleotide encoding such polypeptides, vectors comprising such polynucleotides, collection of vectors comprising such polynucleotides and use of such polypeptides, polynucleotides, vectors for treating or preventing diseases, in particular tumor diseases. The teleost invariant chain polypeptides or fragments thereof act as “T cell enhancer” converting non-immunogenic antigenic sequences into immunogenic T cell antigens.Type: ApplicationFiled: October 18, 2019Publication date: December 9, 2021Inventors: Alfredo NICOSIA, Elisa SCARSELLI, Armin LAHM
-
Publication number: 20210379170Abstract: The present invention relates to a method for selecting cancer neoantigens for use in a personalized vaccine. This invention relates as well to a method for constructing a vector or collection of vectors carrying the neoantigens for a personalized vaccine. This invention further relates to vector and collection of vectors comprising the personalized genetic vaccine and the use of said vectors in cancer treatment.Type: ApplicationFiled: November 15, 2019Publication date: December 9, 2021Inventors: Alfredo NICOSIA, Elisa SCARSELLI, Armin LAHM, Guido LEONI
-
Publication number: 20210363201Abstract: The present invention relates to polypeptides comprising a fragment of a teleost invariant chain optionally fused to one or more antigens or a teleost invariant chain fused to one or more antigens or antigenic fragments thereof, a polynucleotide encoding such polypeptides, vectors comprising such polynucleotides, collection of vectors comprising such polynucleotides and use of such polypeptides, polynucleotides, vectors for treating or preventing diseases, in particular tumor diseases. The teleost invariant chain polypeptides or fragments thereof act as “T cell enhancer” converting non-immunogenic antigenic sequences into immunogenic T cell antigens.Type: ApplicationFiled: November 2, 2018Publication date: November 25, 2021Inventors: Alfredo NICOSIA, Elisa SCARSELLI, Armin LAHM, Antonella FOLGORI
-
Patent number: 11098324Abstract: The present invention relates to novel adenovirus strains with a high immunogenicity and no pre-existing immunity in the general human population. The lack of pre-existing immunity is due to novel hypervariable regions in the adenoviral capsid protein hexon. The novel adenovirus strains also have an improved capacity for reproduction. The present invention provides nucleotide and amino acid sequences of these novel adenovirus strains, as well as recombinant viruses, virus-like particles and vectors based on these strains. Further provided are pharmaceutical compositions and medical uses in the therapy or prophylaxis of a disease, and methods for producing an adenovirus or virus-like particles utilizing the novel sequences, recombinant viruses, virus-like particles and vectors.Type: GrantFiled: July 5, 2018Date of Patent: August 24, 2021Assignee: Nouscom AGInventors: Alfredo Nicosia, Stefano Colloca, Armin Lahm
-
Publication number: 20210154277Abstract: Provided herein are methods and compositions for treating a subject having cancer by administering to the subject a neoantigen-based vaccine composition and a long acting, IL-2RP?-selective agonist composition comprised of compounds of Formula (I), and optionally, an anti-PD-1 antibody.Type: ApplicationFiled: November 6, 2018Publication date: May 27, 2021Inventors: Jonathan ZALEVSKY, Alfredo NICOSIA, Elisa SCARSELLI, Anna Morena D'Alise